Nasal Congestion News and Research

RSS

Vitamin D may help reduce incidence, severity of viral respiratory tract infections: Study

Vitamin D may help reduce the incidence and severity of viral respiratory tract infections including influenza, according to a new study conducted by investigators at Greenwich Hospital and Yale University School of Medicine.

16 Jun 2010

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London on June 7th. The results will be presented by the study's principal investigator Prof. Eric Bateman.

4 Jun 2010

Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA

VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.

2 Jun 2010

Study demonstrates efficacy of CONCERTA in treating ADHD in presence of comorbid learning disability

Turning in assignments, following instructions and focusing on learning something new are among the daily classroom challenges for children with Attention Deficit Hyperactivity Disorder (ADHD), according to the National Institute of Mental Health (NIMH). New data presented today show efficacy of CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) on ADHD symptoms in children with the condition who also may face other specific challenges.

26 May 2010

Spring weather determines severity of allergy symptoms

With record-setting snowfall and wet weather in the region this winter, one question comes to mind for many as spring approaches: how bad will my allergies be?

10 Mar 2010

UK pharmacists overwhelmingly prefer dispensing preservative-free drugs

MeadWestvaco Corp. announced today results from an online survey of 100 pharmacists in the UK regarding their preference for dispensing preservative-free nasal medications. The survey showed that 67 percent of UK pharmacists have a preference for dispensing a preservative-free drug. This percentage increased significantly to 84 percent after the benefits of preservative-free drugs were reviewed with these pharmacists.

24 Feb 2010

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston’s safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.

23 Feb 2010

New data from phase 3 study of avanafil for treatment of ED announced

VIVUS, Inc. today announced new data from an analysis of the recently completed phase 3 study (REVIVE TA-301) of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED).

11 Jan 2010

Majority of Canadians confuse sinusitis with H1N1 symptoms

It's winter, that great Canadian season of snow, ice, grey skies...and colds and the flu. In a year when H1N1 is high on everyone's radar, it is more important than ever for Canadians to know what their symptoms mean and when they should see their doctor.

17 Dec 2009

Knowledge gaps exist among physicians in diagnosis and management of food allergy

With an estimated four to six percent of children in the U.S. suffering from food allergies, a new study shows that pediatricians and family physicians aren't always confident they have the ability to diagnose or treat food allergies.

10 Dec 2009

Positive results from REVIVE, a phase 3 pivotal study of avanafil announced

VIVUS, Inc. today announced positive results from REVIVE (TA-301), a phase 3 pivotal study evaluating the safety and efficacy of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED), in 646 patients.

18 Nov 2009

Treatment of allergic rhinitis can improve nasal and ocular symptoms

The treatment of allergic rhinitis is shown to improve co-existing conditions including conjunctivitis, asthma, sinusitis, otitis media with effusion (fluid in the middle ear) and sleep disorders according to an international expert at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.

10 Nov 2009

Breathe Right "Extra" to help consumers sleep better at night

While many of us will never know the feeling of playing in a professional football game, we all should know the feeling of getting a good night's sleep. However, many adults suffer from night-time congestion, a good night's sleep can be as elusive as a speedy running back - until now.

15 Oct 2009

Four H1N1 vaccines approved by FDA

The U.S. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. The vaccines will be distributed nationally after the initial lots become available, which is expected within the next four weeks.

16 Sep 2009

Eat healthy foods to prevent flu

As flu season grips the nation with heightened awareness of hand washing and cough covering, healthy eating is a potent prevention method getting left out in the cold.

14 Sep 2009

FDA approves Meda's ASTEPRO Nasal Spray

Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.

2 Sep 2009

Herbalscience research throws light on causes of allergic rhinitis

Most people might think of nettle as simply a common and aggressive weed that can sting and cause skin irritation. But nettle has also been used for hundreds of years to treat seasonal allergies and other inflammatory diseases, although the precise nature of its anti-inflammatory effect was unknown. Now, scientists with HerbalScience have identified specific bioactives in nettle leaf extracts that inhibit in vitro receptors and enzymes known to be key in generating symptoms of allergic rhinitis, or hay fever.

26 Aug 2009

FDA approve Fanapt tablets (iloperidone) to treat adults with schizophrenia

The U.S. Food and Drug Administration has approved Fanapt tablets (iloperidone) to treat adults with schizophrenia, a chronic, severe and disabling brain disorder.

7 May 2009

Generics less effective than branded counterparts in treating lower urinary tract symptoms

Men taking generic drugs may be more likely to have less effective results and more adverse events than if they were using branded medications, according to new data from researchers in New York.

26 Apr 2009

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009